Retension Pharmaceuticals
retensionpharmaceuticals.com
Actively hiring
Health Care
Biologics & Biosimilars
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$22.4M
2 rounds on record
Latest round
$12.3M
Venture round · Apr 2025 · 17 mo ago
Team
51-200
employees, estimated range
The money's age
Due for its next round
17 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 22, 2025
Raised a round Venture round $12.3M · SEC Form D
Nov 21, 2023
Raised a round Venture round $10.1M · SEC Form D
2023
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Apr 2025 | $12.3M | — | SEC Form D |
| Venture round | Nov 2023 | $10.1M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Retension Pharmaceuticals, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Eric KellerExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming HBV treatment for cure and advancing…
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company.
Stelexis BioSciences is a clinical-stage biopharmaceutical company created to accelerate novel treatments that aim to eradicate…
Nuance Pharma are an innovation focused biopharmaceutical company, with both late-stage clinical pipeline and commercial stage asset…
Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The…
We partner with top biopharmaceutical companies and research institutions to discover and advance novel therapeutics.
Overview
Retension Pharmaceuticals is a clinical-stage biopharmaceutical company developing RTN-001 and next-generation therapies for uncontrolled hypertension.
People
Eric Keller
Executive Officer, Director
Michael Berendt
Director
Donald Olds
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
3
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
McLean
United States
HQ
Kirkland
United States
Regional office
The unmet need
Sources: World Health Organization, Global report on hypertension (2025); Kirkland EB, et al., J Am Heart Assoc. 2018
Falls Church
United States
Regional office
Retension Pharmaceuticals, Inc.
1104 West Broad Street #1029, Falls Church, VA 22046